# CT-95 in Advanced Cancers Associated With Mesothelin Expression

> **NCT06756035** · PHASE1 · RECRUITING · sponsor: **Context Therapeutics Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Mesothelin-Expressing Tumors
- Epithelial Ovarian Cancer
- Malignant Pleural Mesothelioma, Advanced
- Malignant Peritoneal Mesothelioma, Advanced
- Pancreatic Adenocarcinoma Advanced or Metastatic
- Lung Adenocarcinoma Metastatic
- Cholangiocarcinoma Advanced
- Cholangiocarcinoma Non-resectable
- Mesothelin-expressing Advanced Cancers
- Mesothelin-positive Advanced Malignant Solid Tumors
- Colorectal Cancer

## Interventions

- **DRUG:** CT-95

## Key facts

- **NCT ID:** NCT06756035
- **Lead sponsor:** Context Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-31
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06756035

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06756035, "CT-95 in Advanced Cancers Associated With Mesothelin Expression". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06756035. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*